Evidence map›Paper›PMID 27730471›Full record

ArticleMolecular imaging and biology2017

Monitoring Tumor Response after Liposomal Doxorubicin in Combination with Liposomal Vinorelbine Treatment Using 3'-Deoxy-3'-[

Chun-Yi Wu, Jo-Hsin Tang, Pei-Chia Chan, Jia-Je Li, Ming-Hsien Lin, Chih-Chieh Shen, Ren-Shyan Liu, Hsin-Ell Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular imaging and biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact, top 86% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 1 country.

Chun-Yi WuDepartment of Biomedical Imaging and Radiological Science, China Medical University, Taichung, Taiwan.
Jo-Hsin TangDepartment of Biomedical Imaging and Radiological Sciences, National Yang-Ming University, Taipei, Taiwan.
Pei-Chia ChanDepartment of Biomedical Imaging and Radiological Sciences, National Yang-Ming University, Taipei, Taiwan.
Jia-Je LiDepartment of Biomedical Imaging and Radiological Sciences, National Yang-Ming University, Taipei, Taiwan.
Ming-Hsien LinDepartment of Nuclear Medicine, Taipei City Hospital Zhongxiao Branch, Taipei, Taiwan.
Chih-Chieh ShenDepartment of Nuclear Medicine, Cheng Hsin General Hospital, Taipei, Taiwan. chihchieh0330@yahoo.com.tw.
Ren-Shyan LiuDepartment of Biomedical Imaging and Radiological Sciences, National Yang-Ming University, Taipei, Taiwan.
Hsin-Ell WangDepartment of Biomedical Imaging and Radiological Sciences, National Yang-Ming University, Taipei, Taiwan. hewang@ym.edu.tw.
National Yang Ming University Hospital · TWCheng Hsin General Hospital · TWChina Medical University · TWElectronics Testing Center · TWNational Yang Ming Chiao Tung University · TWNational Yang Ming Chiao Tung University · TWTaipei City Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeSurgical resection is the standard treatment for localized colorectal cancer, which is the most common type of gastrointestinal cancer. However, over 40 % cases are diagnosed metastasized and apparently inoperable. Systemic chemotherapy provides an alternative to these patients. This study aims to evaluate the therapeutic potential of liposomal doxorubicin (lipoDox) in combination with liposomal vinorelbine (lipoVNB) in a CT-26 colon carcinoma-bearing mouse model. PROCEDURES: The in vitro cytotoxicity of Dox and VNB on CT-26 cancer cells was determined by MTT and colony formation assays. Mice were subcutaneously inoculated with 2 × 10

resultsBased on the results of pharmacokinetic study, co-administration of lipoDox and lipoVNB did not affect their individual systemic distribution, while lipoDox retained longer in blood than lipoVNB did. Superior tumor growth retardation was observed in the group received lipoDox plus lipoVNB administration (1 mg/kg each, namely D

conclusionThis study demonstrated that lipoDox in combination with lipoVNB was more efficacious than clinically used regimen, lipoDox plus VNB, in the treatment of colon carcinoma and [

Indexed as

Positron-Emission TomographyAnimalsAntineoplastic Combined Chemotherapy ProtocolsCell DeathCell Line, TumorCell ShapeDideoxynucleosidesDoxorubicinImmunohistochemistryMiceNeoplasmsPolyethylene GlycolsTime FactorsTissue DistributionTomography, Emission-Computed, Single-PhotonTomography, X-Ray ComputedalovudineDideoxynucleosidesDoxorubicinliposomal doxorubicinPolyethylene GlycolsVinblastineVinorelbine[18F]FLTColon carcinomaLiposomal doxorubicinLiposomal vinorelbineTherapeutic efficacy

Identifiers

PMID27730471
OpenAlexW2530907197

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.